Work

P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial.

Year: 2011

Type: article

Study design: Clinical Trial

Source: Cancer Research

DOI: 10.1158/0008-5472.sabcs11-p1-17-10

Authors: SM Tolaney, H Nechushtan, R Berger, R Kurzrock, IG Ron, P Schöffski, A Awada, CA Yasenchak, HA Burris, DA Ramies, X Shen, EP Winer

Institutions: The University of Texas MD Anderson Cancer Center, Exelixis (United States), Tel Aviv Sourasky Medical Center, Sheba Medical Center, Hadassah Medical Center, Universitair Ziekenhuis Leuven, Institut Jules Bordet, Sarah Cannon, Dana-Farber Cancer Institute

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2315499684

FWCI: 0.432

Cites:

Cited by: 5

Related to: 10